Napoleone Ferrara is an Italian molecular biologist. Born July 26, 1956, in Catania. Educated at University of Catania and University of California, San Francisco. Awards include Lasker-DeBakey Clinical Medical Research Award, Breakthrough Prize in Life Sciences and Canada Gairdner International Award.
Facts
20 facts · 1 confirmed by two sources · 6 cited · 13 from one source
Where this comes from
Papalocal keeps its own record. It started from these sources; what each one said is kept here as it was copied, so a change on their side never changes this page by itself. Tap one to read its version.
What Wikidata says · copied November 19, 2026 · revision 2527150906
- Described as
- Italian molecular biologist
- Born
- July 26, 1956
- Born in
- Catania
- Citizen of
- United States
- Occupation
- biologist; physician; molecular biologist; researcher · 1 reference
- Worked for
- University of California, San Diego
- Education
- University of Catania; University of California, San Francisco
- Member of
- National Academy of Sciences; Accademia Nazionale dei Lincei (2025–) · 1 reference
- Awards
- Lasker-DeBakey Clinical Medical Research Award (2010) · 1 reference; Breakthrough Prize in Life Sciences (2013) · 1 reference; Canada Gairdner International Award (2014); Scientific Grand Prize of the Lefoulon-Delalande Fondation (2005) · 1 reference; Dr. Paul Janssen Award for Biomedical Research (2011) · 1 reference; Champalimaud Vision Award (2014); Clarivate Citation Laureates (2018) · 1 reference
- Field
- endothelium
- Wikipedias with a page
- 12
Wikidata item Q1769254 (wikidata.org/wiki/Q1769254), public domain (CC0). Copied November 19, 2026.
What Wikipedia says · copied November 19, 2026 · revision 1372332465
Napoleone Ferrara (born 26 July 1956 in Catania, Sicily, Italy) is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy. At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development and FDA approval of the first clinically effective angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor. Bevacizumab, first approved for treatment of metastatic colorectal cancer in 2004, has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in patients with intraocular neovascular disorders such as neovascular AMD and retinal vein occlusion. Ranibizumab and other anti-VEGF agents represent the first effective therapy for such blinding disorders and rank among the most widely used drugs in older adults.
- Born, in its opening lines
- July 26, 1956
From the Wikipedia article “Napoleone Ferrara” (en.wikipedia.org/wiki/Napoleone_Ferrara), by its contributors, under CC BY-SA 4.0 (creativecommons.org/licenses/by-sa/4.0/). Copied November 19, 2026; not changed.
Confirmed Two sources agree. Cited One source, and it names where it got it. One source One source, without a reference of its own. Sources disagree The sources disagree. We show the best-supported value and keep theirs below.